Moser H W
Department of Neurology and Pediatrics, Kennedy Institute, Johns Hopkins University, Baltimore, Maryland.
Curr Opin Neurol Neurosurg. 1992 Jun;5(3):355-8.
For the 36 known lysosomal disorders the main diagnostic advance is the identification of the gene defect with the demonstration of heterogeneity for each. Therapies that involve enzyme replacement or bone marrow transplantation are evolving. An increasing number of peroxisomal disorders are being identified. Combined liver-kidney transplantation are beneficial for hyperoxaluria type I, and dietary therapy and bone marrow transplantation appear to benefit patients with X-linked adrenoleukodystrophy.
对于36种已知的溶酶体疾病,主要的诊断进展是确定基因缺陷,并证明每种疾病的异质性。涉及酶替代或骨髓移植的治疗方法正在不断发展。越来越多的过氧化物酶体疾病被发现。肝肾联合移植对I型高草酸尿症有益,饮食疗法和骨髓移植似乎对X连锁肾上腺脑白质营养不良患者有益。